Invivyd Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
19.5%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$63.3Mnext fiscal year
FY EPS (est.)
-$0.53next fiscal year
Monitoring Framework
Key Performance Indicators
PEMGARDA Net Product Revenue Quarterly13.7MTarget: Sustained commercial growth in immunocompromised populations
Cash and Cash Equivalents Quarterly184.2MTarget: Sufficient runway through key clinical milestones
VYD2311 Phase 3 DECLARATION Trial Enrollment QuarterlyTarget: Completed enrollment (announced June 2026)
Watch Items
- VYD2311 Phase 3 DECLARATION Topline Data ReadoutTrigger: Anticipated in Q3 2026Action: Evaluate efficacy, safety, and neutralizing activity against dominant circulating SARS-CoV-2 variants to support BLA pathway.
- Going Concern and Cash Burn RateTrigger: Accumulated deficit of $995.9M and substantial doubt about ability to continue as a going concern beyond one yearAction: Monitor usage of the at-the-market (ATM) offering facility and potential dilutive capital raises to extend operational runway.
- FDA Regulatory Stance and Fact Sheet UpdatesTrigger: FDA updates to PEMGARDA Fact Sheet regarding susceptibility to circulating variants (e.g., KP.3.1.1)Action: Assess impact on healthcare provider adoption, commercial demand, and potential need to pivot to next-generation candidates.
Research as of 19 Jun 2026